---
title: "Buy Rating Reaffirmed on Litigation Progress, Price Target Maintained at $5900"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296601286.md"
description: "Jefferies analyst David Hayes reaffirmed a Buy rating on Reckitt with a $5,900 price target, citing the Abbott NEC litigation settlement as a constructive step toward resolving legal overhang. Bernstein also maintained a Buy rating with a £75.00 target."
datetime: "2026-08-21T09:55:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296601286.md)
  - [en](https://longbridge.com/en/news/296601286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296601286.md)
generator: "portal-rs"
---

# Buy Rating Reaffirmed on Litigation Progress, Price Target Maintained at $5900

Jefferies analyst David Hayes maintained a Buy rating on Reckitt today and set a price target of p5,900.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

David Hayes has given his Buy rating due to a combination of factors linked to the recent Abbott NEC litigation settlement and its implications for Reckitt. He views Abbott’s roughly £500m ($670m) agreement, which resolves the Gill damages and about 2,000 additional higher‑credibility claims, as a constructive step that signals accelerating progress toward broader resolution of NEC cases.

Hayes believes this development increases the likelihood that Reckitt can also reach a substantial settlement in the near term, which would significantly reduce legal overhang and uncertainty that has weighed on investor sentiment. With the litigation risk beginning to clear while the fundamental investment case remains intact, he maintains his positive stance and keeps his price target unchanged at $5900.

In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a £75.00 price target.

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [RKT.UK](https://longbridge.com/en/quote/RKT.UK.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [RBGLY.US](https://longbridge.com/en/quote/RBGLY.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [RBGLD.US](https://longbridge.com/en/quote/RBGLD.US.md)

## Related News & Research

- [Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/296461096.md)
- [Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?](https://longbridge.com/en/news/296546525.md)
- [Abbott agrees to $670 million settlement of infant formula cases](https://longbridge.com/en/news/296534956.md)
- [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md)
- [Clark & Stuart Inc Has $3.12 Million Position in Abbott Laboratories $ABT](https://longbridge.com/en/news/295898933.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**